热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
PerCP/Cyanine5.5 anti-human HLA-DR Antibody
产品名称：
PerCP/Cyanine5.5 anti-human HLA-DR Antibody
产品类别：
抗体
产品编号：
307629
产品应用：
307629
[价格]
规格 价格 库存
25tests ￥ 2112 1

产品详情

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Chimpanzee, Dog, Common Marmoset, Squirrel Monkey, Cotton-topped Tamarin
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DRa which depends on the correct folding of the a? heterodimer.19

Additional reported applications (for the relevant formats) include: immunoprecipitation8, Western blotting8, in vitro blocking of mixed lymphocyte reactions9,10, depeletion of MHC class II cells7,?immunohistochemical staining of acetone-fixed frozen sections4,5, and spatial biology (IBEX)21,22. For sensitive functional assays, we recommend using the Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) (Cat. No. 307648, 307665 - 307669).

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Brodsky F. 1984. Immunogenetics 19:179.
  2. Robbins P, et al. 1987. Human Immunol. 18:301.
  3. Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
  4. Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
  5. Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
  6. Zipf T, et al. 1981. Cancer Res. 41:4786.
  7. Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
  8. Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
  9. Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
  10. Wang RF, et al. 1999. Science 284:1351. (Block)
  11. Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
  12. Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
  13. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  14. Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
  15. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  16. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  17. Stein R, et al. 2011. Leuk. Lymphoma 52:273.
  18. Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
  19. Moro M, et al. 2005. BMC Immunol. 6:24.
  20. Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed
  21. Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
  22. Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
Product Citations
  1. Rha MS, et al. 2021. Immunity. 54:44. PubMed
  2. Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed
  3. Ohlsson S, et al. 2014. Clin Immunol. 152:10. PubMed
  4. Kubo M, et al. 2018. Oncol Rep. 39:417. PubMed
  5. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
  6. Elston L, et al. 2020. Br J Haematol. 188:872. PubMed
  7. Price A, et al. 2016. Proc Natl Acad Sci U S A. 113: 10678 - 1068. PubMed
  8. Levin M, et al. 2013. J Immunol. 191:551. PubMed
  9. Mottok A, et al. 2015. Cell Rep. 13:1418-31. PubMed
  10. Iannetta M, et al. 2016. PLoS One. 11: 0160277. PubMed
  11. Zhang D, et al. 2020. Oncoimmunology. 9:1744921. PubMed
  12. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  13. Luo Y, et al. 2021. Front Immunol. 12:761209. PubMed
  14. Kalina T, et al. 2020. Front Immunol. 11:371. PubMed
  15. Kanderova V, et al. 2016. Mol Cell Proteomics. 15: 1246-1261. PubMed
  16. Oh DY, et al. 2020. Cell. 181:1612. PubMed
  17. Fraccarollo D, et al. 2021. eLife. 0.416666666666667. PubMed
  18. Port JR, et al. 2020. J Virol. 94:. PubMed
  19. Nilsson JS, et al. 2019. Oncol Lett. 2.484027778. PubMed
  20. Fredriksson K, et al. 2014. J Immunol. 192:4497. PubMed
  21. Cavrois M, et al. 2019. PLoS One. 14:e0221181. PubMed
  22. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  23. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  24. Moreno-Fernandez ME, et al. 2021. STAR Protoc. 2:100937. PubMed
  25. Ireland RE, et al. 2022. Viruses. 14:. PubMed
  26. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  27. Pi J, et al. 2022. J Nanobiotechnology. 20:36. PubMed
  28. Parker R, et al. 2021. Cell Reports. 35(8):109179. PubMed
  29. Masuda N, et al. 2021. BMC Cancer. 21:1269. PubMed
  30. Domanska D, et al. 2022. J Exp Med. 219:. PubMed
  31. Weinberg A, et al. 2015. PLoS One. 10:122431. PubMed
  32. D’Abramo A, et al. 2016. PLoS One. 11: 0149601. PubMed
  33. Salumets A, et al. 2022. Aging Cell. 21:e13607. PubMed
  34. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  35. Cytlak U, et al. 2020. Immunity. 53(2):353-370. PubMed
  36. Walker‐Sperling VE et al. 2017. EBioMedicine. 16:141-149 . PubMed
  37. van Dongen JJM, et al. 2019. Front Immunol. 10:1271. PubMed
RRID
AB_893575 (BioLegend Cat. No. 307629) AB_893567 (BioLegend Cat. No. 307630)

Antigen Details

Structure
Ig superfamily, MHC class II, heterodimeric transmembrane protein, 36 kD heavy and 27 kD light chain
Distribution

B cells, activated T cells, monocytes/macrophages, dendritic cells, other APCs

Function
Peptide presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, Macrophages, Monocytes, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
2. Terstappen L, et al. 1990. J. Leukocyte Biol. 48:138.
3. Edwards JA, et al. 1986. J. Immunol. 137:490.
4. van Es A, et al. 1984. Transplantation 37:65.
5. O'Doherty U, et al. 1994. Immunology 82:487.
6. Thomas R, et al. 1994. J. Immunol. 153:4016.
7. Grouard G, et al. 1996. Nature 384:364.

Gene ID
3122 View all products for this Gene ID 3123 View all products for this Gene ID
UniProt
View information about HLA-DR on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线